This article was originally published in The Tan Sheet
CEO Jan Leschly will retire following the annual general meeting for shareholders April 28, five months before he reaches mandatory retirement age. Leschly, 59, became chief exec of SB in 1994; he joined the company in 1990 as chairman of the worldwide pharmaceutical business. Under Leschly, SmithKline's consumer healthcare division moved to number two worldwide with the 1994 acquisition of Sterling Winthrop. It has grown recently with the company's launch of the NicoDerm CQ and Nicorette OTC smoking cessation products. Chief Operating Officer Jean-Pierre Garnier will succeed Leschly; the company does not expect to name a new COO
You may also be interested in...
Manufacturing streamlining initiatives undertaken by Glaxo Wellcome and SmithKline Beecham in 1999 may have already begun the cost savings that can be expected from the combination of the British firms.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC